A major driver of the biology of hypoxic tumours is the transcription factor HIF-1α (Carmeliet et al, 1998), which is responsible not alone for altered gene expression, but also may contribute to cancer progression and the development of a phenotype more refractory to therapy (Harris, 2001). Here, HIF1A is linked to neoplasm.